KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Intangibles (2016 - 2025)

Acadia Pharmaceuticals has reported Intangibles over the past 9 years, most recently at $108.9 million for Q4 2025.

  • Quarterly results put Intangibles at $108.9 million for Q4 2025, down 9.09% from a year ago — trailing twelve months through Dec 2025 was $108.9 million (down 9.09% YoY), and the annual figure for FY2025 was $108.9 million, down 9.09%.
  • Intangibles for Q4 2025 was $108.9 million at Acadia Pharmaceuticals, down from $111.6 million in the prior quarter.
  • Over the last five years, Intangibles for ACAD hit a ceiling of $119.8 million in Q4 2024 and a floor of $369000.0 in Q2 2021.
  • Median Intangibles over the past 4 years was $106.7 million (2024), compared with a mean of $84.0 million.
  • Biggest five-year swings in Intangibles: crashed 80.01% in 2021 and later skyrocketed 82.9% in 2024.
  • Acadia Pharmaceuticals' Intangibles stood at $369000.0 in 2021, then surged by 17647.97% to $65.5 million in 2023, then surged by 82.9% to $119.8 million in 2024, then dropped by 9.09% to $108.9 million in 2025.
  • The last three reported values for Intangibles were $108.9 million (Q4 2025), $111.6 million (Q3 2025), and $114.3 million (Q2 2025) per Business Quant data.